Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

ObjectiveADAPT+ assessed the long-term safety, tolerability, and efficacy of efgartigimod in adult participants with generalized myasthenia gravis (gMG).MethodsADAPT+ was an open-label, single-arm, multicenter, up to 3-year extension of the pivotal phase 3 ADAPT study. Efgartigimod was administered...

Full description

Bibliographic Details
Main Authors: James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Jan L. De Bleecker, Hiroyuki Murai, Andreas Meisel, Said R. Beydoun, Mamatha Pasnoor, Antonio Guglietta, Benjamin Van Hoorick, Sophie Steeland, Caroline T’joen, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, the ADAPT+ Study Group
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1284444/full